Precipio Reports Q2 2024 Revenue Of $4.4M Vs $4.33M Est; Expects Pathology Division's Revenues Will Reach More Than $1.5M Per Month By Year End

7/17/24 9:21:55 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $PRPO alert in real time by email

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago.

Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals.

Get the next $PRPO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRPO

Date	Price Target	Rating	Analyst

More analyst ratings

$PRPO
Financials

Live finance-specific insights

Precipio Announces Q3-2024 Shareholder Update Call
Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400
11/6/24 5:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
Precipio Announces Q2-2024 Shareholder Update Call
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10191990/fd50f1a89e and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions in advance shou
8/15/24 5:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
Precipio Announces Year end 2023 Shareholder Update Call
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10187530/fbf7985e7e and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questio
3/25/24 5:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials

$PRPO
Press Releases

Fastest customizable press release news feed in the world

Precipio Announces Q3-2024 Shareholder Update Call
Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400
11/6/24 5:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024). This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other
10/8/24 10:00:00 AM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and success. "The company's achievement of its milestones would not have been possible without the hard work and dedication of its employees. Management believes it is in the shareholders' i
9/6/24 4:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials

$PRPO
Leadership Updates

Live Leadership Updates

Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib
3/21/22 5:00:00 PM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
89bio Announces Appointment of Kathy LaPorte to its Board of Directors
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien
11/3/21 8:00:00 AM ET
$BOLT
$ETNB
$PRPO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f
3/3/21 11:00:00 AM ET
$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials

Precipio Reports Q2 2024 Revenue Of $4.4M Vs $4.33M Est; Expects Pathology Division's Revenues Will Reach More Than $1.5M Per Month By Year End

Chat with this insight

Recent Analyst Ratings for
$PRPO

$PRPO
SEC Filings

Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Precipio Inc.

Precipio Inc. filed SEC Form 8-K: Leadership Update

$PRPO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Sandberg Richard A sold $12,558 worth of shares (2,000 units at $6.28), decreasing direct ownership by 11% to 16,525 units (SEC Form 4)

Director Valauri Christina Rizopoulos was granted 1,472 shares, increasing direct ownership by 41% to 5,021 units (SEC Form 4)

Director Sandberg Richard A was granted 2,492 shares, increasing direct ownership by 16% to 18,525 units (SEC Form 4)

$PRPO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Precipio Inc.

$PRPO
Market Insights

Live Market Insights

Precipio Reports $0.3M Cash Generated By Operations In Q2 2024

Precipio shares are trading higher after the company reported a Q2 revenue beat.